233 related articles for article (PubMed ID: 25043476)
21. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
[TBL] [Abstract][Full Text] [Related]
24. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
25. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
[TBL] [Abstract][Full Text] [Related]
26. Prevention of human papillomavirus-associated cancers.
Dillner J
Semin Oncol; 2015 Apr; 42(2):272-83. PubMed ID: 25843731
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
28. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
29. Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Cheung L; Wacholder S; Burk RD
Int J Cancer; 2012 Oct; 131(8):1874-81. PubMed ID: 22213126
[TBL] [Abstract][Full Text] [Related]
30. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
31. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.
Del Mistro A; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Girlando S; Rizzolo R; Frayle H; Trevisan M; Sani C; Burroni E; Giorgi Rossi P; Cuzick J; Ronco G;
Int J Cancer; 2018 Jul; 143(2):333-342. PubMed ID: 29453769
[TBL] [Abstract][Full Text] [Related]
32. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.
Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Hernandez-Avila M; Brown DR; Elbasha E; Muñoz N; Paavonen J; Haupt RM;
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):287-96. PubMed ID: 21300618
[TBL] [Abstract][Full Text] [Related]
33. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
34. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
35. Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions.
Schmitt M; Depuydt C; Benoy I; Bogers J; Antoine J; Pawlita M; Arbyn M;
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):406-14. PubMed ID: 23334590
[TBL] [Abstract][Full Text] [Related]
36. Five-year risk of CIN3 after short-term HPV-DNA negativity in cytology-negative women: a population-based cohort study.
Del Mistro A; Giorgi Rossi P; Frayle H; Pasquale L; Campari C; Ronco G; Zorzi M
BJOG; 2019 Oct; 126(11):1365-1371. PubMed ID: 31356722
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.
Dovey de la Cour C; Guleria S; Nygård M; Trygvadóttir L; Sigurdsson K; Liaw KL; Hortlund M; Lagheden C; Hansen BT; Munk C; Dillner J; Kjaer SK
Cancer Med; 2019 Feb; 8(2):839-849. PubMed ID: 30632704
[TBL] [Abstract][Full Text] [Related]
38. Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection.
Jensen KE; Schmiedel S; Frederiksen K; Norrild B; Iftner T; Kjær SK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):1949-55. PubMed ID: 23019238
[TBL] [Abstract][Full Text] [Related]
39. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K
Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
Castle PE; Solomon D; Schiffman M; Wheeler CM
J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
